Biotechnology
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
* End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure strategies * End-of-treatment data from ENHANCE did not demonstrate improved HBsAg loss rates compared to ...
2026-07-03 08:00
5326
SK bioscience Launches AI-Powered Initiative to Reduce Uncertainty in Vaccine-Development Decisions
* SK bioscience was selected to lead the Gates Foundation-funded ROTOR project, establishing a global collaboration framework. * SK bioscience, PATH, Slalom, and SK AX will jointly develop an AI-powered platform for evidence-based clinical development decision-making. * The project will supp...
2026-07-02 20:00
3860
Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery
Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration a...
2026-07-02 10:16
4098
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
SUZHOU, China and MÖLNDAL, Sweden, July 2, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with Madrigal Pharmaceuticals, Inc. (Madrigal, NASDAQ: MDGL) announce the successful...
2026-07-02 09:29
3557
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
SHANGHAI, July 1, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN) to jointly advance the clinical development of a novel I...
2026-07-02 09:00
3514
Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-Class Single-Domain Antibody-Based BBB-Crossing Technology for CNS Diseases
CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, today announced a strategic collaboration with Lonza to develop best-in-class single-domain antibody–base...
2026-07-02 08:05
3644
PharmaResearch Accelerates REJURAN Cosmetics Expansion Across North and South America with Planned Acquisition of CG USA
Acquisition strengthens local manufacturing and logistics capabilities as REJURAN Cosmetics expands across Sephora, Amazon and Canada, with future growth across the Americas in view SEOUL, South Korea, July 1, 2026 /PRNewswire/ -- PharmaResearch, the South Korea-based regenerative medicine comp...
2026-07-01 13:38
4969
Colossal Foundation and University of Tasmania Partner to Combat Devil Facial Tumour Disease with Vaccines and Gene Editing
The collaboration leverages Colossal's marsupial de-extinction and conservation biotechnology platform to save the Tasmanian devil from a contagious cancer that has driven 80% population declines across Tasmania DALLAS and HOBART, Australia, July 1, 2026 /PRNewswire/ -- The Colossal Foundation, ...
2026-07-01 07:00
2973
ALR Technologies Announces Strategic Acquisition of CGM Medical Technology for US$45 Million & 200M Shares
SINGAPORE, June 30, 2026 /PRNewswire/ -- ALR Technologies SG Ltd ("ALRT" or the "Company") (OTC: ALRTF), the diabetes management company, announces it has entered into a Letter of Intent ("LOI") to acquire 100% equity of CGM Medical Technology Singapore Pte. Ltd. ("CGM Medical Singapore") and ass...
2026-06-30 23:26
9100
Pictor® Holdings Inc. Secures $7.5 Million Bridge Round to Accelerate Commercialization of Targeted Proteomic Platform
Investment brings Pictor's total capital raised to approximately $30 million, supporting expanded U.S. and international commercialization efforts CARLSBAD, Calif., June 30, 2026 /PRNewswire/ -- Pictor Holdings Inc., a global targeted proteomic platform company headquartered in Carlsbad, Califor...
2026-06-30 23:02
2608
Tsingke Biotech Hosts Shanghai Salon on Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeutics
SHANGHAI, June 30, 2026 /PRNewswire/ -- Tsingke Biotech recently hosted the Oligonucleotide Drug Salon at the Hilton Shanghai Zhangjiang, bringing together experts from academia, biopharmaceutical companies, investment firms, and industry service organizations to discuss technological innovation,...
2026-06-30 22:17
3585
New Human Study in Nature's Scientific Reports Finds Candela's Nordlys® Non-Ablative Fractional Laser Reverses the Skin's Epigenetic Signature of Aging
First in vivo human evidence that Candela's Nordlys laser remodels DNA
methylation associated with skin aging and has a direct molecular link to skin
cancer biology
MARLBOROUGH, Mass., June 30, 2026 /PRNewswire/ -- A new peer-reviewed study
published today in Scientific Reports
2026-06-30 21:52
3431
Shantha Biologics Announces Cartridge Fill-Finish Collaboration
HYDERABAD, India, June 30, 2026 /PRNewswire/ -- Shantha Biologics today announced that it has entered into an outsourcing agreement with Novo Nordisk to provide cartridge fill-finish manufacturing services in India. The agreement with Novo Nordisk reflects Shantha Biologics' continued focus on h...
2026-06-30 21:47
3284
Bota Biosciences and BASF Introduce Bio-Identical Collagen III Powered by AI
PULNOY, France and HANGZHOU, China, June 30, 2026 /PRNewswire/ -- Bota Biosciences and BASF jointly announced the market launch of BASF's SkinNexus™ Collag3n. This 100% human-identical recombinant Collagen III fragment was developed in collaboration between the two companies and is being commerc...
2026-06-30 21:00
2392
Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth
* Advanced environmental performance through renewable energy transition and enhanced carbon transparency * Strengthened sustainability management and supply chain engagement across the healthcare value chain INCHEON, South Korea, June 30, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.K...
2026-06-30 19:00
3201
CU Medicine Ranked World No. 2 in Gastroenterology & Hepatology
HONG KONG, June 30, 2026 /PRNewswire/ -- U.S. News & World Report has again ranked The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) No. 2 globally in Gastroenterology & Hepatology, maintaining a top-three position worldwide for four consecutive editions. The Faculty ...
2026-06-30 17:43
1960
WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy
WUXI, China, June 30, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi — Drug Substance Facility 2 (MFG2) and Drug Product Facility 1 (DP1) — together ...
2026-06-30 13:49
2399
EirGenix Showcases Dual-Track Biosimilars and CDMO Strategy in U.S. Market Push at BIO 2026
SAN DIEGO, June 30, 2026 /PRNewswire/ -- At BIO 2026, EirGenix presented its comprehensive HER2-positive breast cancer biosimilar portfolio and highlighted its integrated one-stop contract development and manufacturing organization (CDMO) service platform. The company actively pursued U.S. market...
2026-06-30 13:36
2591
Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...
2026-06-30 12:00
3079
Xellar Raises $50 Million Series A Financing to Build the Future of 3D Bio Intelligence
Financing will accelerate the development of human-relevant biological data infrastructure, virtual cell technologies, and next-generation drug discovery BOSTON, June 29, 2026 /PRNewswire/ -- Xellar Biosystems today announced the closing of $50 million in Series A and A+ financing to advance its ...
2026-06-30 10:06
2168
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 317 media titles]
2026-09-03 23:53
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 311 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 307 media titles]
2026-09-01 11:00
DayOne and TNB Explore Up To 1.5 GW of On-Site Power Generation to Advance Malaysia's Energy Resilience and Digital Economy
[Picked up by 292 media titles]
2026-09-01 17:36Most Read
Klook Takes Creator Commerce Beyond Influence With Kreator Shops
2026-09-01 11:00
6724
YY Group Enters New Era as YYForce, Expanding AI, Automation and Human-Robot Workforce Strategy; Nasdaq Ticker Changes to "YFOR"
2026-09-01 04:10
6354
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
2026-09-02 12:17
6142
